ESMO Immuno-Oncology Congress 2021

Dec 8 - Dec 11 2021

58P - Validation of the Achilles VELOSTM Process 2 manufacturing platform for the treatment of solid cancer: GMP scale runs generate a significant dose boost of highly potent clonal neoantigen reactive T cells

Supporting Materials

Print Page
RSS Feeds
Email Alerts
Contact IR